ELVN
Enliven Therapeutics, Inc.
Next earnings Aug 11, 2026 · consensus $-0.42 EPS
Last earnings -2.2% on 2026-05-07
$48.60
▲ +5.74%$48.60▲ +122.94%
over 1Y
L $15.14EODHDH $48.60
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+5.7%
1W+14.2%
1M+14.3%
3M+56.0%
YTD+212.7%
1Y+122.9%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Buy
Conservative balance sheet (liabilities/equity 0.04x).
Enliven Therapeutics, Inc. shows limited reported revenue, and -22.6% ROE.
Sources: SEC EDGAR (CIK 0001672619, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 9:49:37 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.